Literature DB >> 9498161

Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis.

A Mussi1, C Bonifati, M Carducci, G D'Agosto, F Pimpinelli, D D'Urso, L D'Auria, M Fazio, F Ameglio.   

Abstract

UNLABELLED: TNF-alpha is a pleiotropic cytokine possibly involved in the pathogenesis of psoriasis.
OBJECTIVE: to analyze the serum TNF-alpha levels in plaque-type psoriatic patients to evaluate the concentrations, correlation with the severity score and behaviour after therapy. The serum TNF-alpha levels of thirty-seven patients (25 females and 12 males; median age: 52.5 years, range 18-81: median PASI score: 11.4, range 3.5-42) and thirty healthy controls (21 females and 9 males, median age: 48.5 years, range 25-77) were compared after measurements obtained employing commercially available ELISA kits. The median serum TNF-alpha levels of the patients were significantly higher than those of controls (p = 0.004). 30/37 patients were followed over time at 2 and 4 weeks of treatment. Twenty one subjects were also observed after 6 weeks. After effective treatments, both the PASI scores and the cytokine levels were significantly and concomitantly reduced (p < 0.001). Significant correlations were found when the TNF-alpha values were plotted against the PASI scores both at the time of patient enrollment and at all the subsequent times (118 observations). A significant correlation was observed between circulating TNF-alpha and sE-selectin in agreement with a possible functional activity of the cytokine. However, no correlation was found between the cytokine levels and other 4 soluble membrane molecules. Our findings indicate that the molecule studied, although non specific for the disease considered, presents a behaviour paralleling that of the disease severity and therefore might have clinical usefulness, particularly in monitoring the therapeutic effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9498161

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  28 in total

Review 1.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

2.  The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease.

Authors:  H Sigmundsdóttir; J E Gudjónsson; I Jónsdóttir; B R Lúdvíksson; H Valdimarsson
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

Review 3.  Psoriasis: advances in pathophysiology and management.

Authors:  A MacDonald; A D Burden
Journal:  Postgrad Med J       Date:  2007-11       Impact factor: 2.401

Review 4.  Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective.

Authors:  David Kane; Oliver FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

Review 5.  Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications.

Authors:  Jie Wang; Yow-Ming C Wang; Hae-Young Ahn
Journal:  AAPS J       Date:  2014-07-04       Impact factor: 4.009

6.  Psoriasiform Sarcoidosis: Collision of Two Entities or Expression of One Common Pathogenesis?

Authors:  Miriam L Vega; Jennifer Abrahams; Matthew Keller
Journal:  J Clin Aesthet Dermatol       Date:  2016-04-01

7.  Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic source.

Authors:  Grigory A Efimov; Andrei A Kruglov; Zoya V Khlopchatnikova; Fedor N Rozov; Vladislav V Mokhonov; Stefan Rose-John; Jürgen Scheller; Siamon Gordon; Martin Stacey; Marina S Drutskaya; Sergei V Tillib; Sergei A Nedospasov
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-02       Impact factor: 11.205

8.  Circulating Th17, Th22, and Th1 cells are increased in psoriasis.

Authors:  Shinji Kagami; Heather L Rizzo; Jennifer J Lee; Yoshinobu Koguchi; Andrew Blauvelt
Journal:  J Invest Dermatol       Date:  2009-12-24       Impact factor: 8.551

9.  Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.

Authors:  Jochen Schmitt; Gottfried Wozel
Journal:  Biologics       Date:  2009-07-13

10.  Prevalence of metabolic syndrome in South Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome: a hospital-based case-control study.

Authors:  Shraddha Madanagobalane; Sankarasubramanian Anandan
Journal:  Indian J Dermatol       Date:  2012-09       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.